Enliven therapeutics announces updated positive data from phase 1 clinical trial of elvn-001 in cml and oral presentation at the eha 2025 congress

Reported cumulative mmr rate of 44% (16 of 36) by 24 weeks with 26% (7 of 27) of patients achieving mmr by 24 weeks, which continues to compare favorably to precedent phase 1 trials of approved bcr::abl1 tkis elvn-001 continues to demonstrate a favorable safety and tolerability profile across all dose levels with 74 patients enrolled and a median treatment duration of ~26 weeks at cutoff presentation at eha will include updated data with additional patients and longer treatment duration enliven will host a webcast and conference call on june 13 at 1:30 p.m. et boulder, colo.
ELVN Ratings Summary
ELVN Quant Ranking